Recent Posts
- HealthInvest June 2026: A Look Inside Australia’s Healthcare Innovations
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences
- Lifesaving Capital: How impact investing is shaping the future of biotech
- Investor Relations: the quiet advantage powering ASX microcaps
- HealthInvest Sydney: Life Sciences in the Investor Spotlight
Archives
HaemaLogiX's Tertia Dex explains the KappaMab antibody
HaemaLogix's Chief Manufacturing and Development Officer, Tertia Dex, explains the fascinating process to manufacture KappaMab, a highly-targeted antibody designed to treat mutliple myeloma.
